Please login to the form below

Not currently logged in
Email:
Password:

Ovid Therapeutics adds member to scientific advisory board

Dr Jerome Zeldis joins the firm
ovid Therapeutics

New York-based Ovid Therapeutics has appointed Dr Jerome Zeldis to its scientific advisory board.

Ovid is a privately-held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain.

Dr Zeldis has been noted for his successful experience in drug development and previously served as Celgene's senior VP of clinical research and medical affairs.

Prior to joining Celgene in 1997, Dr Zeldis was associate director of clinical research at Sandoz Research Institute and director of medical development at Janssen Pharmaceutical Research Institute.

He said: “Ovid is pursuing an ambitious approach of tackling rare neurological diseases with significant unmet needs. With this goal, the company has assembled a world-class leadership and is employing a science-based approach to target new pathways that are involved in these diseases.

“I look forward to working closely with Ovid's team.”

Jeremy Levin, CEO and chairman of Ovid, added: “We are delighted and privileged to welcome Jerry to our scientific advisory board.

“Jerry's advice and insight will be extremely valuable as we enter the clinic.”

12th October 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Iguazu

Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...

Latest intelligence

Patient engagement
Taking a holistic approach to patient care
The importance of recognising each patient as an individual...
The concordance conundrum – the tech divide
“Hello? Can you hear me? I think you are on mute” – how many times have we all heard this over the past five or so months? Not exactly the...
3 ways to increase patient retention rates in clinical trials
Retention rates are falling in clinical trials. Yes, it is a bit disheartening. But there are some straightforward things you can do to turn it around....

Infographics